Following the early 2022 acquisition of e-Zyvec, integration activities have focused on providing a deeper level of solutions support to customers. Using the proprietary e-Zyvec technology, plasmids are assembled de novo, from a library of DNA bricks, removing the use of standard backbones that contain undesired DNA sequences. Plasmids can be engineered from scratch in a record short time window of only two weeks using the Polyplus online plasmid engineering tool. These engineered plasmids can then be chosen for the delivery of the gene of interests used in gene therapies.

“We are now one of few companies in the market that can provide a fully customizable plasmid engineering service,” said Mario Philips, CEO at Polyplus. “This innovative and rapid plasmid engineering service will help the Viral Vector industry to optimize process economics for advanced therapy manufacturing and enable customers to achieve their ambitious Time to Market goals.”

“The Transgene Plasmid Engineering Services are a great complement to the existing transfection reagent portfolio. We can support customers in the design and optimisation of their transgene before it is transfected in producing cells for viral vector production,” Sylvain Julien, Innovation Director at Polyplus commented. “Throughout each step of the process, we are working in close relation with our customers to make sure that the final plasmid design will fit their expectations.”

Transgene Services are currently available to engineer custom plasmids for viral vector manufacturing processes. An online portal (D-Zyvec) enables interested parties to initiate a project and start drawing their ideal plasmid. The drawings are moved into an interaction with Polyplus experts to evaluate feasibility, enhance design, and deliver best-in-class plasmids for the process. The from scratch engineered plasmids can be available in a period of only two weeks.